Nouscom
Clinical-stage biotech developing neoantigen-based cancer immunotherapies.
€120MSeries D
ParticipantEL
EQT Life Sciences
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
- Rounds participated in
- 6
- Confirmed lead rounds
- 0 5 roles undisclosed
- New companies
- 6 First participation on record · 0 follow-on
- Funding in participating rounds
- $664.8M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
6 in this selectionVaderis Therapeutics
Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia
$152MSeries B
Role not disclosedRQ Bio
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
$115MSeries A
Role not disclosedTenpoint Therapeutics
Develops treatments to rejuvenate vision in the aging eye
$235MSeries B
Role not disclosedExciva
Develops novel therapies for behavioral symptoms associated with Alzheimer's Disease
€51MSeries B
Role not disclosedKinaset Therapeutics
Develops inhaled therapies for severe respiratory diseases
$103MSeries B
Role not disclosed